| 2025 |
A precision medicine approach to primary immunodeficiency disease: Ataluren strikes nonsense mutations once again |
Articolo in rivista |
Go to |
| 2025 |
Rescuing nonsense in cancer: recovering p53 tumor suppressor gene expression by
translational readthrough inducing drugs (TRIDs) |
Poster pubblicato in volume |
Go to |
| 2024 |
Promoting readthrough of nonsense mutations in CF mouse model: Biodistribution and efficacy of NV848 in rescuing CFTR protein expression |
Articolo in rivista |
Go to |
| 2023 |
Readthrough Approach Using NV Translational Readthrough-Inducing Drugs (TRIDs): A Study of the Possible Off-Target Effects on Natural Termination Codons (NTCs) on TP53 and Housekeeping Gene Expression |
Articolo in rivista |
Go to |
| 2023 |
Shaping 1,2,4-Triazolium Fluorinated Ionic Liquid Crystals |
Articolo in rivista |
Go to |
| 2023 |
Production of CHM R293X cell model system to study the rescue of the Rab Escort Protein-1 expression by TRIDs nonsense suppression activity |
Abstract in atti di convegno pubblicato in volume |
Go to |
| 2023 |
Investigating the inhibition of FTSJ1 a tryptophan tRNA-specific
2’-O-methyltransferase by NV TRIDs, as a mechanism of readthrough in
nonsense mutated CFTR |
Articolo in rivista |
Go to |
| 2022 |
P015 Translational readthrough inducing drugs: a study of toxicity in mice models and in vitro safety validation of the specific readthrough process. |
Contributo in atti di convegno pubblicato in rivista |
Go to |
| 2022 |
Readthrough Inducing Drugs (TRIDs) in human fibroblasts harboring the c.5047 C>T (R1683*) nonsense mutation |
Abstract in atti di convegno pubblicato in volume |
Go to |
| 2022 |
Nonsense codons suppression. An acute toxicity study of three optimized TRIDs in murine model, safety and tolerability evaluation |
Articolo in rivista |
Go to |
